- Home
- APPF vs MIRM Comparison
APPF vs MIRM Comparison
Compare APPF & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APPF | MIRM |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 5.7B |
| IPO Year | 2015 | 2019 |
Fundamental Metrics
Financial Performance| Metric | APPF | MIRM |
|---|---|---|
| Price | $163.65 | $92.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | ★ $286.78 | $119.85 |
| AVG Volume (30 Days) | 315.7K | ★ 924.9K |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ 1.18 | N/A |
| Revenue | ★ $950,822,000.00 | $19,138,000.00 |
| Revenue This Year | $19.69 | $26.22 |
| Revenue Next Year | $16.70 | $22.04 |
| P/E Ratio | $140.91 | ★ N/A |
| Revenue Growth | ★ 19.72 | N/A |
| 52 Week Low | $142.73 | $45.17 |
| 52 Week High | $325.90 | $114.99 |
Technical Indicators
Market Signals| Indicator | APPF | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 50.15 | 43.44 |
| Support Level | $161.13 | $87.26 |
| Resistance Level | $165.95 | $98.03 |
| Average True Range (ATR) | 7.71 | 4.98 |
| MACD | 0.82 | -1.16 |
| Stochastic Oscillator | 47.50 | 17.04 |
Price Performance
Historical ComparisonAbout APPF AppFolio Inc.
AppFolio Inc provides cloud-based software solutions for the real estate industry. Its property management software offers property managers an end-to-end solution to their business needs. The group's products include cloud-based property management software (Appfolio Property Manager). Its solutions are AppFolio Property Manager Core, AppFolio Property Manager Plus, and AppFolio Property Manager Max. It also offers value-added services, such as screening, risk mitigation, and electronic payment services. Its markets are Single-Family, Multifamily, Student Housing, Affordable Housing, Community Associations, Commercial, and Investment Management. The business activity of the firm predominantly functions in the United States and it generates revenue in the form of subscription fees.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.